Pulse Biosciences (NASDAQ:PLSE) Sets New 52-Week High – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) reached a new 52-week high during trading on Wednesday . The company traded as high as $48.10 and last traded at $46.00, with a volume of 525728 shares traded. The stock had previously closed at $46.79.

Wall Street Analyst Weigh In

A number of brokerages have commented on PLSE. Wall Street Zen lowered shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Mizuho set a $45.00 price target on Pulse Biosciences in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Canaccord Genuity Group lifted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday. They set a “buy” rating and a $58.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Stock Up 1.8%

The company’s fifty day simple moving average is $32.56 and its two-hundred day simple moving average is $25.67. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of -40.55 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities research analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of PLSE. Russell Investments Group Ltd. increased its position in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the period. Osterweis Capital Management Inc. bought a new stake in Pulse Biosciences in the 2nd quarter valued at $28,000. Alliancebernstein L.P. lifted its position in Pulse Biosciences by 6.7% in the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.